Elevation Oncology bags $65M to push failed Merrimack drug through PhII
Shawn Leland hadn’t even heard of NRG1 as an oncology target until he was sitting in a presentation at ESMO 2018 in Munich. Alex Drilon, an oncologist at the Memorial Sloan Kettering Cancer Center in New York, was presenting on targeted therapies for lung cancer — and Leland was enthralled.
“He put up one slide within that presentation that described the target of NRG1 gene fusion and the fact that they were potentially druggable with a HER3 monoclonal antibody approach,” Leland said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.